[1]白殊同,佟 丽,王 琴,等.过山枫活性成分扁蒴藤素药理作用研究进展[J].中国药理学通报,2019,(03):318-321.[doi:10.3969/j.issn.1001-1978.2019.03.006]
 BAI Shu-tong,TONG Li,WANG Qin,et al.Research advance in molecular mechanism of pharmacological actions of pristimerin[J].Chinese Pharmacological Bulletin,2019,(03):318-321.[doi:10.3969/j.issn.1001-1978.2019.03.006]
点击复制

过山枫活性成分扁蒴藤素药理作用研究进展()
分享到:

《中国药理学通报》[ISSN:/CN:]

卷:
期数:
2019年03期
页码:
318-321
栏目:
讲座与综述
出版日期:
2019-03-14

文章信息/Info

Title:
Research advance in molecular mechanism of pharmacological actions of pristimerin
文章编号:
1001-1978(2019)03-0318-04
作者:
白殊同1佟 丽2王 琴1邓 颖3吴 斌1
1.重庆市中医院中医药防治自身免疫疾病重庆市重点实验室,重庆 400021; 2. 南方医科大学中医药学院,广东 广州 510515; 3. 重庆市中医院中医妇科,重庆 400021
Author(s):
BAI Shu-tong1 TONG Li2 WANG Qin1 DENG Ying3 WU Bin1
1.Chongqing Key Lab of Traditional Chinese Medicine to Prevent and Treat Autoimmune Diseases,Chongqing Hospital of Traditional Chinese Medicine, Chongqing 400021,China; 2. School of Traditional Chinese Medicine,Southern Medical University, Guangzhou 510515, China; 3. TCM Gynecology Dept, Chongqing Hospital of Traditional Chinese Medicine, Chongqing 400021,China
关键词:
扁蒴藤素 过山枫 肿瘤 类风湿关节炎 研究进展 药理作用
Keywords:
pristimeirn Celastrus aculeatus Merr. tumor rheumatoid arthiritis research advance pharmacological action
分类号:
R-05; R282.71; R284.1; R593.220.22; R730.22
DOI:
10.3969/j.issn.1001-1978.2019.03.006
文献标志码:
A
摘要:
扁蒴藤素是中药过山枫的主要活性成分,近年来关于扁蒴藤素的抗肿瘤和抗类风湿关节炎药理作用研究日渐增多。该文通过对扁蒴藤素研究文献进行综述,分析其药理作用特点和相关分子机制,以期为扁蒴藤素的新药开发和临床应用提供参考。
Abstract:
Pristimeirn, as one major active chemical component of traditional Chinese medicine Celastrus aculeatus Merr., has been reported to have pharmacological activities such as broad spectrum anti-tumor and anti-rheumatoid arthritis in recent years. In this article, we review the research articles of pristimerin on the characteristics and molecular mechanism of its pharmacological effects, aiming to make a reference for new drug development and clinical application.

参考文献/References:

[1] Tang W H, Bai S T, Tong L, et al. Chemical constituents from Celastrus aculeatus Merr[J]. Biochem Syst Ecol, 2014, 54:78-82.
[2] Yang H, Landis-Piwowar K R, Lu D, et al. Pristimerin induces apoptosis by targeting the proteasome in prostate cancer cells[J]. J Cell Biochem, 2008, 103(1): 234-44.
[3] Liu Y B, Gao X, Deeb D, et al. Ubiquitin-proteasomal degradation of antiapoptotic survivin facilitates induction of apoptosis in prostate cancer cells by pristimerin[J]. Int J Oncol, 2014, 45(4): 1735-41.
[4] Liu Y B, Gao X, Deeb D, et al. Role of telomerase in anticancer activity of pristimerin in prostate cancer cells[J]. J Exp Ther Oncol, 2015, 11(1): 41-9.
[5] Lee S O, Kim J S, Lee M S, et al. Anti-cancer effect of pristimerin by inhibition of HIF-1α involves the SPHK-1 pathway in hypoxic prostate cancer cells[J]. BMC Cancer, 2016, 16(1): 701.
[6] Zuo J, Guo Y, Peng X, et al. Inhibitory action of pristimerin on hypoxiamediated metastasis involves stem cell characteristics and EMT in PC-3 prostate cancer cells[J]. Oncol Rep, 2015, 33(3): 1388-94.
[7] Huang S, He P, Peng X, et al. Pristimerin inhibits prostate cancer bone metastasis by targeting PC-3 stem cell characteristics and VEGF-induced vasculogenesis of BM-EPCs[J]. Cell Physiol Biochem, 2015, 37(1): 253-68.
[8] Wu C C, Chan M L, Chen W Y, et al. Pristimerin induces caspase-dependent apoptosis in MDA-MB-231 cells via direct effects on mitochondria[J]. Mol Cancer Ther, 2005, 4(8):1277-85.
[9] Lee J S, Yoon I S, Lee M S, et al. Anticancer activity of pristimerin in epidermal growth factor receptor 2-positive SKBR3 human breast cancer cells[J]. Biol Pharm Bull, 2013, 36(2): 316-25.
[10] Mu X M, Shi W, Sun L X, et al. Pristimerin inhibits breast cancer cell migration by up-regulating regulator of G protein signaling 4 expression[J]. Asian Pac J Cancer Prev, 2012, 13(4): 1097-104.
[11] Xie G, Yu X, Liang H, et al. Pristimerin overcomes adriamycin resistance in breast cancer cells through suppressing Akt signaling[J]. Oncol Lett, 2016, 11(5): 3111-6.
[12] Cevatemre B, Erkisa M, Aztopal N, et al. A promising natural product, pristimerin, results in cytotoxicity against breast cancer stem cells in vitro and xenografts in vivo through apoptosis and an incomplete autopaghy in breast cancer[J]. Pharmacol Res, 2018, 129(1): 500-14.
[13] Yousef B A, Guerram M, Hassan H M, et al. Pristimerin demonstrates anticancer potential in colorectal cancer cells by inducing G1 phase arrest and apoptosis and suppressing various pro-survival signaling proteins[J]. Oncol Rep, 2016, 35(2): 1091-100.
[14] Yousef B A, Hassan H M, Zhang L Y, et al. Pristimerin exhibits in vitro and in vivo anticancer activities through inhibition of nuclear factor-κB signaling pathway in colorectal cancer cells[J]. Phytomedicine, 2018, 40:140-7.
[15] Park J H, Kim J K. Pristimerin, a naturally occurring triterpenoid, attenuates tumorigenesis in experimental colitis-associated colon cancer[J]. Phytomedicine, 2018, 42:164-71.
[16] Zhao H, Wang C, Lu B, et al. Pristimerin triggers AIF-dependent programmed necrosis in glioma cells via activation of JNK[J]. Cancer Lett, 2016, 374(1): 136-48.
[17] Gao X, Liu Y, Deeb D, et al. Anticancer activity of pristimerin in ovarian carcinoma cells is mediated through the inhibition of prosurvival Akt/NF-kappaB/mTOR signaling[J]. J Exp Ther Oncol, 2014, 10(4): 275-83.
[18] Guo Y, Zhang W, Yan Y Y, et al. Triterpenoid pristimerin induced HepG2 cells apoptosis through ROS-mediated mitochondrial dysfunction[J]. J BUON, 2013, 18(2): 477-85.
[19] Wei W, Wu S, Wang X, et al. Novel celastrol derivatives inhibit the growth of hepatocellular carcinoma patient-derived xenografts[J]. Oncotarget, 2014, 5(14): 5819-31.
[20] 高皖皎, 邓秋狄, 白殊同, 等. 佐剂型关节炎大鼠滑膜成纤维细胞模型建立及特征分析[J]. 中国药理学通报, 2015, 31(12): 1693-8.
[20] Gao W J, Deng Q D, Bai S T, et al. Establishment and characteristic analysis of fibroblast-like synoviocytes in rats with adjuvant arthritis[J]. Chin Pharmacol Bull, 2015, 31(12):1693-8.
[21] Tong L, Nanjundaiah S M, Venkatesha S H, et al. Pristimerin, a naturally occurring triterpenoid, protects against autoimmune arthritis by modulating the cellular and soluble immune mediators of inflammation and tissue damage[J]. Clin Immunol, 2014, 155(2): 220-30.
[22] Deng Q, Bai S, Gao W, et al. Pristimerin inhibits angiogenesis in adjuvant-induced arthritic rats by suppressing VEGFR2 signaling pathways[J]. Int Immunopharmacol, 2015, 29(2): 302-13.
[23] Jin Y, Wang Y, Zhao D, et al. Pristimerin attenuates ovalbumin- induced allergic airway inflammation in mice[J]. Int Immunopharmacol, 2016, 38(3): 221-7.
[24] Shaaban A A, El-Kashef D H, Hamed M F, et al. Protective effect of pristimerin against LPS-induced acute lung injury in mice[J]. Int Immunopharmacol, 2018, 59: 31-9.
[25] Kim H J, Park G M, Kim J K. Anti-inflammatory effect of pristimerin on lipopolysaccharide-induced inflammatory responses in murine macrophages[J]. Arch Pharm Res, 2013, 36(4): 495-500.

备注/Memo

备注/Memo:
收稿日期:2018-10-12,修回日期:2018-12-20 基金项目:国家自然科学基金资助项目(No 81673724); 重庆市科学技术委员会基础研究与前沿探索重点项目(No cstc2015jcyjB0383); 重庆市科学技术委员会科研院所绩效激励引导专项(No cstc2017jxjl0242) 作者简介:白殊同(1985-),男,博士,中药师,研究方向:中药治疗自身免疫疾病,E-mail:baishutong@hotmail.com; 吴 斌(1972-),男,博士,主任中医师,博士生导师,研究方向:风湿病的基础与临床,通讯作者,E-mail:wuubinn@163.com
更新日期/Last Update: 2019-03-14